TY - JOUR
T1 - Targeting breast cancer initiating cells
T2 - Advances in breast cancer research and therapy
AU - McCubrey, James A.
AU - Davis, Nicole M.
AU - Abrams, Stephen L.
AU - Montalto, Giuseppe
AU - Cervello, Melchiorre
AU - Libra, Massimo
AU - Nicoletti, Ferdinando
AU - D'Assoro, Antonino B.
AU - Cocco, Lucio
AU - Martelli, Alberto M.
AU - Steelman, Linda S.
N1 - Funding Information:
ABD was supported in part by grants from the USAMRMC BC022276 , the Intramural RECDA Award and the Italian Association for Cancer Research (AIRC). MC and GM were supported in part by grants from MIUR – FIRB-MERIT (RBNE08YYBM). MC was also supported in part by a grant to the CNR from the Italian Ministry of Economy and Finance for the Project FaReBio di Qualità. LC was supported in part by MIUR-PRIN 2009. ML was supported in part by a grant from the Italian Ministry of Health, Ricerca Finalizzata Stemness 2008 entitled “Molecular Determinants of Stemness and Mesenchymal Phenotype in Breast Cancer”. AMM was supported in part by a grant from MIUR FIRB 2011 (RBAP11ZJFA_001).
PY - 2014/9
Y1 - 2014/9
N2 - Over the past 10 years there have been significant advances in our understanding of breast cancer and the important roles that breast cancer initiating cells (CICs) play in the development and resistance of breast cancer. Breast CICs endowed with self-renewing and tumor-initiating capacities are believed to be responsible for the relapses which often occur after various breast cancer therapies. In this review, we will summarize some of the key developments in breast CICs which will include discussion of some of the key genes implicated: estrogen receptor (. ER), HER2, BRCA1, TP53, PIK3CA, RB, P16INK1 and various miRs as well some drugs which are showing promise in targeting CICs. In addition, the concept of combined therapies will be discussed. Basic and clinical research is resulting in novel approaches to improve breast cancer therapy by targeting the breast CICs.
AB - Over the past 10 years there have been significant advances in our understanding of breast cancer and the important roles that breast cancer initiating cells (CICs) play in the development and resistance of breast cancer. Breast CICs endowed with self-renewing and tumor-initiating capacities are believed to be responsible for the relapses which often occur after various breast cancer therapies. In this review, we will summarize some of the key developments in breast CICs which will include discussion of some of the key genes implicated: estrogen receptor (. ER), HER2, BRCA1, TP53, PIK3CA, RB, P16INK1 and various miRs as well some drugs which are showing promise in targeting CICs. In addition, the concept of combined therapies will be discussed. Basic and clinical research is resulting in novel approaches to improve breast cancer therapy by targeting the breast CICs.
KW - Cancer stem cells
KW - ER
KW - HER2
KW - Hormonal therapy
KW - MiRs
KW - Targeted therapy
KW - Therapy resistance
UR - http://www.scopus.com/inward/record.url?scp=84906766048&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84906766048&partnerID=8YFLogxK
U2 - 10.1016/j.jbior.2014.05.003
DO - 10.1016/j.jbior.2014.05.003
M3 - Article
C2 - 24913694
AN - SCOPUS:84906766048
SN - 2212-4926
VL - 56
SP - 81
EP - 107
JO - Advances in Biological Regulation
JF - Advances in Biological Regulation
ER -